section name header

Pronunciation

eye-KAT-i-bant audio

Classifications

Therapeutic Classification:hereditary angioedema agents

Pharmacologic Classification: bradykinin B2 receptor antagonists

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 97% absorbed following SUBQ administration.

Distribution: Unknown.

Metabolism/Excretion: Metabolized systemically by proteolytic enzymes to metabolites that are renally excreted; <10% excreted unchanged in urine.

Half-life: 1.4 hr.

Time/Action Profile

(reduction of symptoms)

ROUTEONSETPEAKDURATION
SUBQwithin 1 hr2.0–2.6 hr†6–8 hr

† 50% reduction in baseline symptoms.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: ↑ transaminases.

Local: injection site reactions.

Neuro: dizziness.

Misc: fever.

Interactions

Drug-Drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Firazyr

Code

NDC Code*